secwatch.observer — SEC 8-K summary
======================================

Issuer:     Quince Therapeutics, Inc. (QNCX)
CIK:        0001662774
Form:       8-K
Filed at:   2026-04-09T23:59:59+00:00
Accession:  0001193125-26-149021
Event type: other_material
Sentiment:  neutral
Materiality: 0.40
Item codes: 3.03, 5.03, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Quince Therapeutics announces 1-for-10 reverse stock split effective April 10, 2026
--------------------------------------------------------------------------------

- Approximately 16.3M shares outstanding post-split; ratio 1-for-10.
- Certificate of Amendment filed with Delaware on April 9; effective 11:59 PM ET April 10.
- Split-adjusted trading on Nasdaq begins at market open April 13; new CUSIP 22053A206.
- Stock options and warrants proportionally adjusted; no change to rights or preferences.
- Equiniti Trust Company appointed as exchange agent; fractional shares paid in cash.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1662774/000119312526149021/0001193125-26-149021-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1662774/000119312526149021/d115661d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-149021

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer